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Dimeric calpains constitute a promising therapeutic target for many diseases such as cardiovascular,
neurodegenerative and ischaemic disease. The discovery of selective calpain inhibitors, however, has
been extremely challenging. Previously, allosteric inhibitors of calpains, such as PD150606, which
included a speciﬁc a-mercaptoacrylic acid sub-structure, were reported to bind to the penta-EF hand
calcium binding domain, PEF(S) of calpain. Although these are selective to calpains over other cysteine
proteases, their mode of action has remained elusive due to their ability to inhibit the active site domain
with and without the presence of PEF(S), with similar potency. These ﬁndings have led to the question of
whether the inhibitory response can be attributed to an allosteric mode of action or alternatively to
inhibition at the active site. In order to address this problem, we report a structure-based virtual
screening protocol as a novel approach for the discovery of PEF(S) binders that populate a novel chemical
space. We have identiﬁed compound 1, Vidupiprant, which is shown to bind to the PEF(S) domain by the
TNS displacement method, and it exhibited speciﬁcity in its allosteric mode of inhibition. Compound 1
inhibited the full-length calpain-1 complex with a higher potency (IC50¼ 7.5 mM) than the selective, cell-
permeable non-peptide calpain inhibitor, PD150606 (IC50¼19.3 mM), where the latter also inhibited the
active site domain in the absence of PEF(S) (IC50¼17.8 mM). Hence the method presented here has
identiﬁed known compounds with a novel allosteric mechanism for the inhibition of calpain-1. We show
for the ﬁrst time that the inhibition of enzyme activity can be attributed to an allosteric mode of action,
which may offer improved selectivity and a reduced side-effects proﬁle.
© 2018 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).ding domain; TNS, p-toluidi-
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Calpains are proteins that belong to the family of calcium-
dependent, non-lysosomal cysteine proteases expressed ubiqui-
tously in mammals and other organisms [1]. Although the physi-
ological roles of calpains are still poorly understood, they have been
shown to be involved in many processes such as cell motility, long-
term potentiation in neurons and cell fusion in myoblasts [2]. In
particular, conventional dimeric calpains have been reported to be
involved in the cell degeneration processes that characterize
numerous disease conditions [3].
Calpain-1 (m-calpain) and calpain-2 (m-calpain) are hetero-
dimeric proteases composed of a large subunit with a molecular
mass of ~80 kDa, sharing a small subunit of mass ~30 kDa. The smallss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cium binding PEF(S) and glycine rich (GR) domains, which are
essential for stabilizing calpain-1 and calpain-2 [4]. High sequence
similarity of 62% is exhibited by the large subunits of calpain-1 and
-2 in humans [4]. And they consist of four different domains, an N-
terminal anchor helix, the active site domain (CysPc), a domain that
resembles the C2 membrane binding domains of phosphokinases,
known as the C2L domain, and a second penta-EF hand calcium
binding domain known as PEF(L). The PEF(L) domain is the deter-
minant of the calcium concentration that is required for protease
activation, which differentiates between the two isoforms: calpain-
1 requires micromolar concentrations of Ca2þ, whereas calpain-2
requires millimolar concentrations for activation [5].
Calpain-1 is a target dysregulated in many diseases such as
neurodegenerative disorders, cardiovascular diseases, ischaemic
disorders, arterial sclerosis, leishmaniasis and cancer [6,7]. In most
cases of disease, calpain-1 activity is elevated (and hence its inhi-
bition would be beneﬁcial in treatment). However, it has been
recently suggested that the up regulation of calpain-1 appears to be
beneﬁcial in some cases, such as stage II Alzheimer's disease, where
its activation could be neuroprotective and beneﬁcial in controlling
cellular damage [8].
Until recently, it has been challenging to design selective
calpain-1 inhibitors, and this is attributed to the fact that most
compounds that target the active site inhibit a broad spectrum of
cysteine proteases, thereby resulting in undesirable side effects [9].
For example, it has been previously reported that calpain-1 in-
hibitors [9], which also inhibit the proteasome may induce
apoptosis, whereas selective calpain-1 inhibitors do not. Hence, it
may be beneﬁcial to design selective calpain-1 inhibitors to avoid
off-target related side effects.
Classical allosteric inhibitors of calpain-1, which were originally
reported to bind to PEF(S), exhibit a very speciﬁc type of chemistry -
that is a-mercaptoacrylic acid-based, such as PD150606 and
PD151746 [10]. These inhibitors are potent, cell permeable andFig. 1. A. PD150606 B. PD151746 bind to the PEF(S) of calpain, and showmodest selectivity fo
and D. respectively, which bind to PEF(S) and were reported [5] with improved potencies in
inhibit the calpain-1 complex (Uniprot IDs: P04632 and P07384) with an IC50 value of 4.9
calpain-1 complex (Uniprot IDs: P04632 and P07384) with an IC50 value of 8 nM and conﬁselective inhibitors of calpain-1 and calpain-2 exhibiting selectivity
towards calpain over other cysteine proteases, with a slight selec-
tivity for calpain-1 over calpain-2. It has been reported however
that PD150606 could equally inhibit the active site domain of
calpain-1 without the presence of PEF(S) [11]. This obviously sug-
gests that its mode of action is rather unclear. The reported a-
mercaptoacrylic acid based calpain inhibitors (Fig. 1. A. PD150606
and B. PD151746) and their disulﬁde analogues (Fig. 1. C. and D.)
were synthesized by Adams et al., and shown to bind to PEF(S) from
X-ray diffraction analysis (PDB IDs: 1NX3, 4WQ2 and 4WQ3)
[5,12e14]. Additional calpain-1 inhibitors that were reported to
inhibit the whole calpain-1 complex, which consists of the PEF(S)
and CysPc (active site domain of calpain-1), are also depicted in
Fig. 1, including their chemical structures. CHEMBL203568 [15],
shown in Fig. 1. E., is a compound reported to inhibit the calpain-1
complex with an IC50 value of 4.9 nM. While CHEMBL204883 [15],
shown in Fig. 1. F., is a compound reported to inhibit the calpain-1
complex with an IC50 value of 8 nM. However, CHEMBL203568 and
CHEMBL204883 have not been conﬁrmed as PEF(S) binders i.e.
exhibit an allosteric mode of inhibition. Their reported conﬁdence
score is 7 (in ChEMBL) indicating that these compounds might be
binding to any of the subunits involved in the full-length calpain-1
complex. Hence, the use of PEF(S) (calpain-1 small subunit) in
structure-based virtual screening may be an appealing approach
for the design of allosteric calpain-1 binders with completely
different structural architecture from the classical allosteric binders
and inhibitors. In addition, this approach is expected to answer the
question of whether PEF(S) binding would confer inhibition, given
that the shortlisting of candidates is based on the prediction of their
binding to PEF(S).
In this work, we have used the PEF(S) (PDB ID: 4WQ2, calpain-1
small subunit) in a structure-based virtual screening protocol to
ascertain whether novel chemical series bind to the allosteric
pocket. To validate this approach, purchasable ligands of diverse
and novel structural frameworks (very different from those thatr calpain-1 over calpain-2. Adams et al., 2015, synthesized their disulphide analogues C.
comparison to their monomer compounds E. CHEMBL203568, a compound reported to
nM and conﬁdence score of 7 F. CHEMBL204883, a compound reported to inhibit the
dence score of 7.
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ligand/protein docking against PEF(S), and the compounds were
subsequently tested in relevant assays. This pipeline for the
structure-based virtual screening protocol is depicted in Fig. 2.
As a general approach, we hypothesised that the functional effect
of PEF(S) binders on the active site of calpain-1 may be predicted by
carryingoutMolecularDynamics (MD)simulations [16,17]on the full-
lengthcalpain-1complex (PEF(S) andCysPc) inboth theunboundand
the ligand bound states to the PEF(S) domain. If the bound compound
increases the average distance between the substrate and the inter-
acting residues in the active site of calpain-1, then we further
hypothesise that it would inhibit the activity of the enzyme. In
contrast, if the compound decreases this distance, itwould favour the
interactions between the enzyme and the substrate, thus facilitating
the enzyme reaction. A crystal structure of the full-length calpain-1Fig. 2. The pipeline of the structure-based virtual screening protocol followed for
shortlisting candidates of PEF(S) binders started with the collection of a pool of
compounds with diverse chemical structures (very different from those that have been
previously investigated), then candidates were shortlisted based on docking into the
crystal structure of PEF(S) (PDB: 4WQ2, calpain-1 small subunit). The top ranked
candidates were assessed for their chemical novelty in comparison to the classical
allosteric binders and inhibitors using an MDS plot. The subset of compounds was then
investigated using relevant experimental assays.complex (PEF(S) and CysPc) is currently unavailable, and hence we
approached the problem by using the pipeline shown in Fig. 2.
Accordingly, the compounds that are predicted to bind to PEF(S) are
either expected to inhibit or activate calpain-1.
To explore the small molecule chemical architecture that would
most likely alter the geometry of the calpain-1 active site, to inhibit
its substrate cleavage allosterically, compounds with diverse
chemical structures were investigated computationally based on
their predicted binding afﬁnities towards PEF(S). The candidate
PEF(S) binders, which were shortlisted by the structure-based vir-
tual screening protocol depicted in Fig. 2 were sulphonamides, N-
{3-[3-(2-alkoxyethoxy)-5-(4-methoxyphenyl)s, and [1,2,4]triazolo
[4,3-b]pyridazin-6-yl]pyridines. Experimentally these compounds
were also shown to bind to PEF(S) by displacing TNS (which binds
to the allosteric site) [10]. In addition, three compounds were able
to inhibit the full-length calpain-1 complex (which includes PEF(S)
and CysPc) allosterically, but not the active site domain of calpain-1
in the absence of PEF(S). The inhibitory activity, via a proposed
allosteric mechanism is a crucial ﬁnding given that they show
speciﬁcity in their mode of action, which is not the case for the
classical allosteric inhibitors such as PD150606. The new inhibitors
possess different scaffolds from the classical allosteric inhibitors.
These compounds serve as a novel starting point for the expansion
of the compound series (including SAR) to improve their potency. In
addition, this ﬁnding suggests that compounds can inhibit the
enzyme activity via the PEF(S) domain. An important aspect of this
study is that by designing allosteric inhibitors, which do not inhibit
the active site domain (that is common to awide variety of cysteine
proteases), these may be effective in treating calpain-1 related
diseases without the side effects associated with inhibitors, which
do inhibit the active site domain as well [18].
2. Results and discussion
2.1. Structure-based virtual screening of purchasable ligands
against PEF(S)
36,503 commercial compounds consisting of diverse chemical
structures (sulphonamide-, amide-, pyridine-, urea-, enamine-
based compounds), were docked using Glide [19] into the pre-
prepared (see methods for details) protein crystal structure of hu-
man PEF(S) (PDB [20]ID: 4WQ2) [5]. From the docking scores, the
distribution for actives versus inactives was obtained. The active
molecules displayed a more favourable distribution of scores,
which allowed differentiation of actives and inactives (see methods
for details).
Candidate PEF(S) binders from the purchasable database were
shortlisted on the basis of a cut-off with the highest Mathews Cor-
relation coefﬁcient. The cut-off obtained was 6.35, according to
which compounds with more negative binding score were predicted
to bind. The selected candidates were further screened against PAINs
[21] (with regard to the recent analysis of the use of this approach
(Tropsha)) [22] using the FAFDrug3 ADME-Tox Filtering Tool [23].
Those compounds that didn't exhibit any potential PAINs liability
were considered for evaluation of calpain-1 activity. As a result, ﬁve
sulphonamides 1e5, two substituted N-{3-[3-(2-alkoxyethoxy)-5-
(4-methoxyphenyl)s 6e7, and three substituted [1,2,4]triazolo [4,3-
b]pyridazin-6-yl]pyridines 8e10, which were the top ranked com-
pounds according to the virtual screening criteria, were shortlisted as
candidates for PEF(S) binding.
2.2. MDS plot shows that shortlisted PEF(S) binders occupy a novel
region in chemical space
An MDS plot of the chemical space was generated consisting of
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plex (PEF(S) and CysPc) with IC50 values 1 mM, and the Adams
library (a library of a-mercaptoacrylic acid calpain inhibitors and
their disulﬁde analogues) [5], which were validated against the
PEF(S) docking model (see methods for details) (Fig. 3). In addition,
the shortlisted candidates 1e10 from the structure-based design
protocol were also included in the plot, which enabled the
assessment of the novelty of chemical space coverage of the
shortlisted PEF(S) binders, in comparison to the classical calpain-1
inhibitors and PEF(S) binders. Fig. 3, which is a two dimensional
MDS plot based on Morgan ﬁngerprints of radius 2 with 90%
ellipse-like conﬁdence regions, shows that the shortlisted com-
pounds 1e10 exhibited new structures in comparison to the pre-
viously reported compounds by occupying a novel region in the
chemical space of calpain-1 actives.Fig. 3. A two dimensional MDS plot based on Morgan ﬁngerprints of radius 2, with 90% elli
Adams et al., [5] and the 10 shortlisted candidates from the structure-based design protoc
binding afﬁnities towards the PEF(S) domain of calpain via docking with Glide. The compoun
compounds that bind to the PEF(S) (Adams library) and the compounds which inhibit the
allosteric inhibitors of calpain-1.2.3. FRET based inhibition assay
A ﬂuorogenic assay of the full-length calpain-1 complex
(which includes PEF(S) and CysPc) was used to determine the
activity of compounds 1e10. Amongst the identiﬁed compounds,
1, 9, and 10 inhibited the full-length calpain-1 complex with IC50
values of 7.5 (±1.1), 20.5 (±1.9), and 29.7 (±5.2) mM, respectively
(Table 1). The same experimental protocol was performed to
measure the activity of compounds against the active site domain
of calpain-1, without the presence of PEF(S), to investigate a
possible allosteric mode of action. None of the compounds
showed any inhibition in the absence of PEF(S), except for
compound 1, which weakly inhibited the active site domain with
an IC50 value >100 mM. In contrast, compound 3 exhibited higher
inhibitory activity against the active site domain of calpain-1pse-like conﬁdence regions for 32 ChEMBL compounds, 33 compounds synthesized by
ol. These were shortlisted from a purchasable database based on their high predicted
ds identiﬁed belong to a new chemical space in comparison to the previously reported
full-length calpain-1 complex. Compounds 1, 9, and 10 were then validated as novel
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length calpain-1 complex, which showed an activity of
>100 mM, suggesting that in the presence of PEF(S) it preferen-
tially binds to PEF(S). This could explain the reduction in its
inhibitory activity since it is most likely unable to alter the ge-
ometry of the active site while it binds allosterically. The IC50
values were also measured for the classical a-mercaptoacrylic
acid based calpain inhibitor, PD150606, and these were 19.3
(±1.6) mM with the full-length calpain-1 complex, and 17.8 (±2.4)
mM with the active site domain without the presence of PEF(S).
Hence, in contrast to compounds 1, 3, 9, and 10, PD150606
exhibited an unspeciﬁc mode of action by equally inhibiting via
both binding sites (active and allosteric sites). It is worth stating
here that compound 1 is an asthma drug, Vidupiprant or AMG
853 [24], which exhibited higher potency than PD150606 in
inhibiting the enzyme activity. The dose response curve of
compound 1 (IC50¼ 7.5 ± 1.1 mM) is displayed in Figure S1.
Interestingly, identifying Vidupiprant as an allosteric inhibitor of
calpain-1 is in agreement with previous reports showing a direct
link between calpain inhibition and anti-inﬂammatory proper-
ties, where it was shown that non-steroidal anti-inﬂammatory
drugs (NSAIDs) inhibit calpain, and that calpain inhibition re-
duces allergic inﬂammation [25,26]. Potentially, this ﬁnding
could highlight the importance of considering calpain inhibitors
for the development of new anti-asthmatic therapies.
The allosteric inhibitory activity exhibited by compounds 1, 9,
and 10 validates the design approach, which shortlisted PEF(S)
binders. The three active compounds include scaffolds, which are
distinct from the classical allosteric inhibitors. The IC50 values
obtained could be improved by efﬁcient choice of substituents
using standard medicinal chemistry approaches. In particular
compound 1, which is a sulphonamide, exhibited speciﬁcity in its
allosteric inhibition of calpain-1, and was more potent (7.5 mM)
than PD150606 (19.3 mM), which additionally inhibits the active
site domain, in the absence of PEF(S), with a similar IC50 value.
2.4. TNS displacement assay
TNS, which is a sensitive ﬂuorophore that binds to PEF(S) was
used to probe protein dynamics and conformational change. It
ﬂuoresces in the bound state i.e. in a hydrophobic environment,
whereas when another compound displaces it, its ﬂuorescence
gets quenched. This ﬂuorophore was used previously to assess the
binding of PD150606 to PEF(S), a compound which has been
already shown to bind to PEF(S) by X-ray crystallography (PDB ID:
1NX3) [10,12]. In this work, PD150606 (as a control), compound 1,
the most potent allosteric inhibitor, compound 3, a weak allosteric
inhibitor, and compounds 2, 4 and 5, which did not exhibit any
inhibitory activity, have been tested for PEF(S) binding by the TNS
displacement method. The results for compounds 6e10 were
unreliable as it became apparent that they ﬂuoresced under the
assay conditions, therefore for this reason these results were
omitted. As shown in Fig. 4, all tested compounds, except for
compound 5, quenched the ﬂuorescence of TNS, exhibiting a
similar trend in their quenching effect to that of the known PEF(S)
binder, PD150606, hence conﬁrming their binding to PEF(S).
Therefore, it appears that compounds 2e4 do indeed bind to
PEF(S) in a similar fashion to compound 1, but they either weakly
inhibited or failed to allosterically alter the geometry of the active
site.
2.5. Analysis of molecular docking studies of representative
calpain-1 inhibitors 1 and 10, and compounds 2e5
Docking studies predicted molecular interactions of thesulphonamide 1 and the [1,2,4]triazolo [4,3-b]pyridazin-6-yl]
pyridine 10 with the PEF(S) protein crystal structure (PDB ID:
4WQ2). Fig. 5. A. shows the 2-chloro-4-cyclopropylsulfonamido
phenyl ring of compound 1 is p-stacked with His131, and the
carbonyl of its carboxylic acid moiety H-bonds with the same
residue, the carbonyl of its amide moiety H-bonds with Trp168,
and the phenyl ring attached to the tert-butylcarbamoyl moiety is
p-stacked with the same residue. Fig. 5. B. shows a p-stacking
interaction between the pyridine ring of compound 10 and Trp168,
and H-bonding of the nitrogen in that ring with the same residue.
The hydrophobic interactions predicted for compounds 1 and 10
with Trp168 are also seen in the co-crystallised ligand/protein
crystal structure (PDB ID: 4WQ3) [5]. In addition, a more favour-
able binding afﬁnity towards PEF(S) was predicted for compound
1 (IC50¼ 7.5 ± 1.1 mM) as compared to compound 10,
(IC50¼ 29.7 ± 5.2 mM), which could be the reason for the higher
inhibitory activity exhibited by compound 1. In order to further
explore the activities of compounds 1e10, MD simulations on the
full-length calpain-1 complex, which includes the PEF(S) domain
would be beneﬁcial once the crystal structure is available. The
inhibitory activity of each compound is predicted to correlate with
the average distance between the substrate and the interacting
residues in the active site of calpain-1.
Docking studies predicted molecular interactions of the sul-
phonamides 2e5 with the PEF(S) protein crystal structure (PDB
ID: 4WQ2), which suggest that the hydrophobic interactions with
Trp168 are essential for PEF(S) binding. Fig. 6. A. shows that the
phenyl ring of compound 2, which is attached to the sulfonyl
moiety is p-stacked with Trp168, and the same residue H-bonds
with the carbonyl of the amide group, the hydroxyl of its cyclo-
hexyl ring H-bonds with Gln100, and its sulfonyl group H-bonds
with His131. Fig. 6. B. displays the predicted molecular interactions
between compound 3 and the PEF(S) crystal structure, and these
are H-bonding between its carboxyl moiety and the Lys172 and
Trp168 residues, H-bonding between its sulfonyl group and His131,
and p-stacking with the Trp168 via its pyridine ring. Fig. 6. C.
demonstrates the predicted molecular interactions for compound
4, the amino group of its amide moiety H-bonds with the Glu97
and Trp168 residues, the phenyl ring of its benzamide group p-
stacks with Trp168, and the carbonyl of its amide moiety H-bonds
with Lys172. Fig. 6. D. shows the H-bonding interactions predicted
for the carbonyl of the oxopyrrolidin-1-yl moiety in compound 5
and the Lys172 and Trp168 residues, and H-bonding interactions for
its sulfonyl moiety with His131, and p-stacking of the same residue
with the with the aromatic ring of its triﬂuoromethylphenyl
moiety. Hence, the hydrophobic interactions predicted for com-
pounds 1e4with Trp168 are also seen in the co-crystallised ligand/
protein crystal structure (PDB ID: 4WQ3) [5]. However, compound
5 was predicted to exhibit hydrophilic interactions with Trp168,
which could explain why it didn't displace TNS, suggesting that
the hydrophobic interactions with this residue are essential for
PEF(S) binding.
2.6. Computational assessment of CNS permeability for
representative calpain-1 inhibitors 1 and 10
Given that calpain-1 may serve as a therapeutic target for
neurodegenerative disorders, the computational assessment of
the CNS permeability for compounds 1 and 10 was performed
with FAFDrug3 [23] to see whether these compounds could be
considered as good starting points to target these diseases. Their
physicochemical properties were calculated using FAFDrug3.
Following this, CNS diagrams were obtained and are presented in
Figure S2. A and B. Compound 1 did not pass the CNS ﬁlter, which
takes into consideration the assessment of its ability to pass the
Table 1
IC50 values for compounds 1e10, and PD150606 determined by the FRET based inhibition assay, with the full-length calpain-1 complex and the active site domain of calpain-1,
reported as mean ± standard deviations from three independent experiments (NR¼ no response).
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L. Kalash et al. / European Journal of Medicinal Chemistry 157 (2018) 1264e12751270blood brain barrier. Hence, it is predicted not to exhibit the
desired permeability [27], since the values of all the descriptors
for compound 1 (logP, HBD, HBA, MW, tPSA (blue line)) fall
outside the CNS ﬁlter area (light blue). As for compound 10, it is
predicted to exhibit medium permeability since all the de-
scriptors, except for the HBA, have passed the CNS ﬁlter. Hence,
compound 10 might serve as a good starting point for analogue
development to target neurodegenerative diseases.Fig. 4. PD150606, which was shown by X-ray crystallography to bind to PEF(S) (PDB ID: 1N
among the identiﬁed allosteric inhibitors, 2 and 4, which did not exhibit any inhibitory activ
of PD150606 conﬁrming their binding to PEF(S), except for compound 5, which neither ex3. Conclusions
In this work, we have successfully validated our structure-
based design method, which has led to the discovery of chemi-
cally novel allosteric inhibitors of calpain-1, and we have shown
for the ﬁrst time an allosteric mode of action. Compounds 1, 9,
and 10 inhibited the full length calpain-1 complex (which in-
cludes PEF(S) and CysPc) with IC50 values of 7.5 (±1.1), 20.5X3), compound 1 (the most potent allosteric inhibitor), 3, which was the least potent
ity, all quenched the ﬂuorescence of TNS. All compounds showed a similar effect to that
hibited any inhibitory activity nor displaced TNS.
Fig. 5. Docking studies predicted molecular interactions of compounds 1 and 10 with the human PEF(S) of calpain-1 small subunit (regulatory subunit) protein crystal structure
(PDB ID: 4WQ2). A. The 2-chloro-4-cyclopropylsulfonamido phenyl ring of compound 1 shows p-stacking with His131 and the carbonyl of its carboxylic acid moiety H-bonds with
the same residue. The carbonyl of its amide moiety H-bonds with Trp168 and the phenyl ring attached to the tert-butylcarbamoyl moiety is p-stacked with the same residue B. The
pyridine ring of compound 10 is p-stacked with Trp168 and the nitrogen of that ring H-bonds with same residue. The hydrophobic interactions of 1 and 10 with Trp168 are also seen
in the co-crystallised ligand/protein crystal structure (PDB ID: 4WQ3) [5].
Fig. 6. Docking studies predicted molecular interactions of the sulphonamides 2e5 with the PEF(S) protein crystal structure (PDB ID: 4WQ2), which suggest that hydrophobic
interactions with Trp168 are essential for PEF(S) binding A. The phenyl ring of compound 2, which is attached to the sulfonyl moiety is p-stacked with Trp168, and the same
residue H-bonds with the carbonyl of its amide group, the hydroxyl of its cyclohexyl ring H-bonds with Gln100, and its sulfonyl group H-bonds with His131 B. H-bonding
interactions are predicted to occur between the carboxyl moiety of compound 3 and the Lys172 and Trp168 residues, H-bonding between its sulfonyl group and His131, and p-
stacking with the Trp168 via its pyridine ring C. The amino group of the amide moiety for compound 4H-bonds with Glu97 and Trp168, and the phenyl ring of its benzamide
group p-stacks with Trp168, and the carbonyl of its amide moiety H-bonds with Lys172 D. H-bonding interactions are predicted to occur between the carbonyl of the oxo-
pyrrolidin-1-yl moiety for compound 5 and the Lys172 and Trp168 residues, H-bonding between its sulfonyl moiety and His131, and p-stacking of the same residue with the with
the aromatic ring of its triﬂuoromethylphenyl moiety.
L. Kalash et al. / European Journal of Medicinal Chemistry 157 (2018) 1264e1275 1271(±1.9), and 29.7 (±5.2) mM respectively. Compounds 9 and 10 did
not inhibit the active site domain of calpain-1 in the absence of
PEF(S), and compound 1 inhibited the active site domain weakly
with an IC50 value >100 mM. In contrast, compound 3 exhibited
higher inhibitory activity against the active site domain ofcalpain-1 with an IC50 value of 41.1 (±15.4) mM as compared to
the full-length calpain-1 complex, which was >100 mM suggest-
ing that it preferentially binds to PEF(S). In addition, the IC50
values were measured for PD150606, giving 19.3 (±1.6) mM with
the full-length calpain-1 complex and 17.8 (±2.4) mM with the
L. Kalash et al. / European Journal of Medicinal Chemistry 157 (2018) 1264e12751272active site domain (without the presence of PEF(S)). In compar-
ison to the classical a-mercaptoacrylic acid based calpain inhib-
itor, PD150606, compounds 1, 9, and 10, exhibited speciﬁcity in
their allosteric mode of action, since they didn't inhibit the active
site domain in the absence of PEF(S).
Furthermore, PD150606, compound 1, the most potent allosteric
inhibitor, compound 3, a weak allosteric inhibitor, and compounds
2 and 4, (which did not exhibit any inhibitory activity) have been
tested for PEF(S) binding by the TNS displacement method. All
compounds (1e4) quenched the ﬂuorescence of TNS, exhibiting a
similar trend in their quenching effect to that of the known PEF(S)
binder, PD150606.
IC50 values obtained for compounds 1, 9, and 10 may be good
starting points for optimisation, having novel scaffolds. Allosteric
inhibitors discovered by this approach could exhibit more selec-
tivity towards calpain-1 since they are unlikely to inhibit the active
site domain, which is similar for a wide variety of cysteine pro-
teases. This could translate to more effective treatments with less
side effects for calpain-1 related diseases [18].
4. Materials and methods
4.1. Extracting purchasable compounds for structure-based virtual
screening against PEF(S), the calpain small subunit 1 (regulatory
subunit)
Purchasable compounds (36,503) with diverse chemistry (sul-
phonamide-, amide-, pyridine-, urea-, enamine-based com-
pounds), were downloaded from the Aldrich market select
database-2016 [28].
4.2. Ligand preparation
The entire set of extracted ligands were prepared for docking
with LigPrep 2.5 [29] using the default settings and the Epik option,
which introduces energy penalties associated with ionization and
tautomerization [30].
4.3. Receptor preparation of PEF(S)
Docking with Glide [19] was performed against human PEF(S),
calpain-1 small subunit (regulatory subunit) of the protein crystal
structure (PDB [20] ID: 4WQ2) [5] bound to (Z)-3-(6-bromondol-3-
yl)-2-mercaptoacrylic acid. The structure was prepared using the
protein preparation wizard of Maestro 9.3 [29], following the
default protocol, which accounts for energy reﬁnement, hydrogen
addition, pKa assignment, and side-chain rotational isomer reﬁne-
ment. Resolved water molecules were discarded and the structure
was centred using the co-crystallised ligand as the centre of the
receptor grid generated for the protein structure. The co-crystal
structure of the human calpain PEF(S) protein crystal structure
(PDB ID: 4WQ2) bound to (Z)-3-(6-bromondol-3-yl)-2-
mercaptoacrylic acid was selected as the target structure.
4.4. Cut-off generation for compound selection from docking model
In an attempt to validate the docking model, a set of known
active and inactive compounds were docked against the PEF(S)
protein crystal structure to ensure that it enriched actives. 32
ChEMBL [31] compounds with IC50 values 1 mM (protein complex
of the calpain-1, catalytic and small regulatory subunits: P07384,
P04632 with conﬁdence scores of 6 or 7) were docked against the
PEF(S) model. In addition, 20 inactive compounds from PubChem
[32] of the PEF(S) calpain-1 small regulatory subunit (Uniprot ID:
P04632) were docked.A good separation was obtained for the medians of docking
score distribution for actives versus inactives for the docking model
indicating that the actives are enriched. Figure S3. shows the sep-
aration of the medians for the PEF(S) docking model, 7.48 (ac-
tives) vs.4.60 (inactives). In addition, the indole and the phenyl a-
mercaptoacrylic acid-based inhibitors and their disulﬁde ana-
logues, which were synthesized by Adams et al., [5] and shown by
X-ray crystallography to bind to PEF(S), were docked against the
PEF(S) dockingmodel. Themedian of the docking score distribution
obtained is 7.25 in comparison to the median of inactives, which
is 4.60 (Figure S4., supporting information), which further vali-
dates that the model enriches these set of actives. Mann-Whitney
test, which included statistical analysis on the active and inactive
docking score distributions, was performed with R [33] using the
script provided by Kalash et al. [34] The differences in the medians
was signiﬁcant with p values less than 0.05.
The Matthews correlation coefﬁcient (MCC), which takes into
account true and false positives and negatives, was computed using
a Python script [34] for all the docking scores of the ChEMBL actives
and PubChem inactives for themodel. A search was performed for a
docking score threshold that gave the highest MCC for the docking
model in order to shortlist purchasable candidates of PEF(S)
binders, which displayed docking scores that are lower than that
with the highest MCC for the PEF(S) docking model (which
was 6.35).
4.5. Docking
The purchasable compounds, prepared according to the protocol
described, were docked against the PEF(S) protein crystal structure
(PDB ID: 4WQ2). The Glide docking parameters included extra
precision (XP) and the ﬂexible ligand sampling option. These were
deduced from docking experiments using known actives and in-
actives against the protein model. The highest ranked compounds
with respect to predicted afﬁnities towards PEF(S) were selected for
binding assessment and calpain-1 activity evaluation i.e. those
which displayed docking scores that are lower than that with the
highest MCC for the PEF(S) docking model, which was 6.35. The
compounds that did not exhibit potential PAINs [21,22] liabilities
upon virtual screening with the FAFDrug3 ADME-Tox ﬁltering tool,
were selected for experimental validation [23]. The shortlisted
compounds exhibited diverse structures, with ﬁve sulphonamides
1e5, two substituted N-{3-[3-(2-alkoxyethoxy)-5-(4-methox-
yphenyl)s 6e7, and three substituted [1,2,4]triazolo [4,3-b]pyr-
idazin-6-yl]pyridines 8e10.
4.6. Multi-dimensional scaling (MDS) analysis of the shortlisted
compounds 1-10
This step of the analysis aimed to plot the chemical space of
ChEMBL compounds, which are active against the full-length cal-
pain-1 complex, with IC50 values 1 mM (protein complex of
calpain-1, catalytic and small regulatory subunits: P07384, P04632
and conﬁdence scores of 6 or 7), and the Adams library [5], which
were validated against the PEF(S) docking model. In addition, the
shortlisted candidates from the structure-based design protocol
were included in the same plot. This analysis enables an assessment
of the novelty of the chemical space coverage of the shortlisted
compounds 1e10. For this purpose, the SMILES of all compounds
involved were standardized using the ChemAxon Command-Line
Standardizer, where the following options were selected:
“Remove Fragment” (keep largest), “Neutralize”, “Remov-
eExplicitH”, “Clean2D”, “Mesomerize” and “Tautomerize” [35].
Subsequently, Morgan ﬁngerprints (radius 2, 1024 bits) were
generated for all the compounds using KNIME 2.11.3 [36]. The
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sequence: It (a) read chemical data from an SDF ﬁle, (b) generated
RDKit molecules from a molecule string representation (SDF), (c)
generated hashed bit-based ﬁngerprints for an input RDKit Mol
column (d) converted RDKit molecules into string based molecule
representations (SDF or smiles) (e) excluded columns from the
input table (f) renamed columns (g) and saved data table into a CSV
ﬁle.
A 2D-similarity matrix based on Euclidean distance was
computed with R, using the generated Morgan ﬁngerprints. Then, a
metric multidimensional scaling of the similarity matrix was
computed by embedding it into two dimensions (k¼ 2). Subse-
quently, a 2D-plot was obtained, with the x-axis and the y-axis
labelled, Dimension 1 and Dimension 2 respectively. These are two
relative and unit-less dimensions that recapitulate the pairwise
similarity of all points observed in the distribution of Euclidean
distances in a lower dimensional space. For each data set in the plot
(corresponding to Adams library, ChEMBL compounds, and the
shortlisted compounds), 90% conﬁdence ellipses were computed
using the ellipse package. Finally, based on the generated Morgan
ﬁngerprints, an MDS plot with 90% ellipse-like conﬁdence regions
was obtained using the R ggplot2 package [37].
4.7. Expression and puriﬁcation of PEF(S)
The codon optimised gene encoding human PEF(S) was pur-
chased from Epoch Biolabs (Texas, USA) in a pET21d vector. Human
PEF(S) was produced in E. coli BL21-CodonPlus (DE3)-RP (Agilent
Technologies), and puriﬁed using the same procedure previously
described for PEF(S) [5].
4.8. Evaluating calpain-1 activity of the shortlisted candidates of
PEF(S) binders 1e10
This assay uses a ﬂuorogenic peptide from the calpain-1 sub-
strate a-spectrin, containing a FAM-DABCYL FRET pair (H2NeK(-
FAM)-EVYGMMK(DABCYL)eOH). Cleavage by calpain-1 occurs
between the Tyr-Gly residues and results in enhanced ﬂuorescence
as the quenching effect is relieved. The assays using puriﬁed
porcine calpain-1 (CalBiochem, 25 nM) were performed in a buffer
containing 1 mM calpain-1 substrate, 10mM HEPES, 10mM DTT,
0.5mM EDTA, bovine serum albumin (0.1%) pH 6.8. The assay was
carried out using a ﬂuorescent plate reader (BMG Optistar) with a
ﬁnal assay volume of 100 ml at a temperature of 37 C, using an
excitation band pass ﬁlter centred at 490 nm and emission detected
at 520 nm. The compounds were added to the assay mixture before
the reaction was initiated by the addition of CaCl2 (5mM). None of
the compounds had signiﬁcant ﬂuorescence at this wavelength.
The compounds were dissolved in DMSO at 40mM and diluted into
assay buffer to give range of concentrations from 5 nM to 200 mM.
In each assay run, the effect of DMSO alone over the concentration
used was also measured. Although there was no effect of DMSO at
lower concentrations, in some assay runs, DMSO at 0.005%e0.5%
produced some inhibitory effect. This DMSO effect (which was only
relevant for compounds with poor inhibitory ability) was sub-
tracted before constructing the inhibition curves [5]. The IC50
values were obtained by ﬁtting the data with non-linear regression
with the SigmaPlot software [38], and the reported results are the
mean± standard deviation of three independent experiments.
4.9. TNS displacement for compounds 1e5
10 mM PEF(S) in 20mM Tris base, 1.1mM CaCl2, 1mM EDTA and
pH 7.4 was incubated with 46.7 mM 2-p-toluidinylnaphthalene-6-
sulfonate (TNS, 1mM stock in 40% ethanol) in a Greiner CELLSTAR96 well black ﬂat bottom plate for 5min at 25 C.
Compounds 1e10 were stored as 40mM stock solutions in
DMSO, then diluted from 500 mM to 500 nM by serial dilution over
10 wells with an Integra Viaﬂow 96 multichannel pipette in
triplicate.
The plates were then incubated in a FLUOstar Omega plate
reader at 25 C for 5min then were analysed using an excitation
wavelength of 355 nm and an emission wavelength of 450 nmwith
10 ﬂashes per well with orbital averaging.
The baseline (just TNS) was subtracted from the ﬂuorescence
(B). B was then subtracted from the Bmax (with no inhibitor) to
invert the data. The datawas plotted in excel as bar diagrams for the
mean ± standard deviation of three independent experiments
(n¼ 3) in triplicate as shown in Fig. 4. Whereas for compounds
6e10, their ﬂuorescence interfered with TNS (refer to Figure S5. for
the blanks obtained for compounds 1e10), for this reason their
results were omitted.
Compounds and reagents Compound 1 was purchased from
Tocris, and compounds 2e10 were purchased from Ambinter, and
used without further puriﬁcation. PD150606 was purchased from
Sigma-Aldrich and used without further puriﬁcation.
4.10. Cloning of CysPC gene
The pET28a-GB1-MAAKLVFF plasmid, a kind gift from Dr Cor-
nelius Krasel of the Institut für Pharmakologie (Marburg, Ger-
many), was used to create a Golden Gate acceptor plasmid by
standard PCR, overlap extension PCR, endonuclease digestion and
T4 DNA ligase reactions. When subjected to Golden Gate digestion/
ligation with BsaI and T4 DNA ligase with an appropriate compli-
mentary PCR product, the resulting plasmid has a section of DNA
encoding RF under a constitutive promotor removed and the PCR
product is incorporated in such a fashion that the translation
product contains the protein of interest with an N-terminal hex-
ahistidine tag GB1 fusion tag that can be removed by the action of
tobacco etch virus protease (TEV).
Digestion/ligation proceeds as expected despite the presence of
an additional BsaI sitewithin the sequence encoding RFP. The CysPC
domain of calpain-1 was inserted into this acceptor by PCRwith the
following primers:
Fwd: CGACTAGTGGTCTCCAGTCCATGGGTCGCCATGAGAA
Rev: CGACTAGTGGTCTCCATCAGTCCGGGGTCAGGTTACA for liga-
tion using the golden gate protocol into the pET28a-GB1-MAAKLVFF
plasmid [39].
4.10.1. Plasmid sequencing
4.10.1.1. T7 fwd. TAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATA
CCATGGGCAGCAGCCATCATCATCATCATCACACTTACAAATTAATCCTT
AATGGTAAAACATTGAAAGGCGAAACAACTACTGAAGCTGTTGATGCT
GCTACTGCAGAAAAAGTCTTCAAACAATACGCTAACGACAACGGTGTT
GACGGTGAATGGACTTACGACGATGCGACTAAGACCTTTACAGTTACTG
AACATATGGAAAACCTGTATTTTCAGTCCGAGACCTTTACGGCTAGCTC
AGCCCTAGGTATTATGCTAGCTACTAGAGAAAGAGGAGAAAAACTAGT
ATGGTTAGCAAAGGCGAGGAGCTGATTAAGGAGAATATGCACATGAA
ACTGTACATGGAAGGCACCGTGAACAACCACCACTTCAAGTGCACCAG
CGAGGGTGAAGGCAAACCGTATGAAGGCACCCAGACCATGCGTATCAA
AGTGGTTGAGGGTGGCCCGCTGCCGTTCGCGTTTGATATTCTGGCGAC
CAGCTTCATGTACGGTAGCCGTACCTTTATCAACCACACCCAGGGCATT
CCGGATTTCTTTAAACAGAGCTTCCCGGAAGGTTTTACCTGGGAGCGTG
TGACCACCTACGAAGACGGTGGCGTTCTGACCGCGACCCAGGACACCA
GCCTGCAAGATGGCTGCCTGATCTATAACGTGAAGATTCGTGGTGTTAA
CTTTCCGAGCAACGGCCCGGTGATGCAGAAGAAAACCCTGGGTTGGGA
GGCGAACACCGAAATGCTGTATCCGGCGGATGGTGGCCTGGAGGGCC
GTAGCGACATGGCGCTGAAGCTGGTTGGTGGCGGTCACCTGATCTGCA
ACTTCAAAACCACC
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TGGTGGTGCTCGAGTTATCAGGAGACCGCTAGTTCAGTTTGTGACCCAG
CTTGCTCGGCAGATCGCAATAACGCGCAACCGCCACTTCGTGTTGCTCA
ACGTAGGTCTCTTTATCCGCTTCCTTAATACGCTCCAGACGGTGATCAAC
ATAGTACACACCCGGCATTTTCAGGTTCTTCGCCGGTTTCTTGCTACGAT
AGGTGGTTTTGAAGTTGCAGATCAGGTGACCGCCACCAACCAGCTTCA
GCGCCATGTCGCTACGGCCCTCCAGGCCACCATCCGCCGGATACAGCAT
TTCGGTGTTCGCCTCCCAACCCAGGGTTTTCTTCTGCATCACCGGGCCG
TTGCTCGGAAAGTTAACACCACGAATCTTCACGTTATAGATCAGGCAGC
CATCTTGCAGGCTGGTGTCCTGGGTCGCGGTCAGAACGCCACCGTCTTC
GTAGGTGGTCACACGCTCCCAGGTAAAACCTTCCGGGAAGCTCTGTTTA
AAGAAATCCGGAATGCCCTGGGTGTGGTTGATAAAGGTACGGCTACCG
TACATGAAGCTGGTCGCCAGAATATCAAACGCGAACGGCAGCGGGCCA
CCCTCAACCACTTTGATACGCATGGTCTGGGTGCCTTCATACGGTTTGC
CTTCACCCTCGCTGGTGCACTTGAAGTGGTGGTTGTTCACGGTGCCTTC
CATGTACAGTTTCATGTGCATATTCTCCTTAATCAGCTCCTCGCCTTTGC
TAACCATAC4.11. Expression and puriﬁcation of CysPC
BL21-CodonPlus (DE3) RP cells containing the human calpain-1
CysPC gene were grown at 37 C in kanamycin selective LB media
until OD600¼ 0.6 then induced with 1mM IPTG. The protein was
expressed overnight at 20 C and cells harvested by centrifugation
in a Sorvall RC6 Plus centrifuge (Thermo Fisher Scientiﬁc, Inc, MA,
USA) using an SLA-3000 rotor at 6080 RCF for 20min at 4 C. The
cells were re-suspended in 20mM HEPES, 100mM NaCl, 0.5mM
TCEP pH 7.6 (buffer A) and lysed by sonication for 5min (pulsed 5 s
on, 10 s off). The lysate was clariﬁed by centrifugation at 4 C for
40min at 30,310 RCF in a Sorvall RC6 Plus centrifuge. The super-
natant was passed through a 0.2 mm syringe ﬁlter and applied to a
Ni-NTA column. The bound protein was washed with 15 C V buffer
A and eluted with 10 C V buffer A containing 250mM imidazole,
which was further dialyzed in buffer A overnight in a 10 kDa
membrane containing 1mL aliquot of TEV protease. The cleavage
product was then passed back through a Ni-NTA column to remove
the 6xHis-GB1 solubility tag and TEV protease, with the ﬂow
through containing active CysPC as conﬁrmed by SDS-PAGE, mass
spectrometry and calpain-1 activity assay.4.12. Expression and puriﬁcation of TEV protease
BL21 (DE3) cells containing the TEV gene codon optimised for
E. coli expression was obtained from Prof. Nigel Richards (Cardiff
University).
The cells containing the TEV protease gene were grown at 37 C
in ampicillin selective LB media until OD600¼ 0.6 then induced
with 1mM IPTG. The protein was expressed overnight at 20 C and
cells harvested by centrifugation in a Sorvall RC6 Plus centrifuge
(Thermo Fisher Scientiﬁc, Inc, MA, USA) using an SLA-3000 rotor at
6080 RCF for 20min at 4 C. The cells were re-suspended in 20mM
HEPES, 100mM NaCl, 0.5mM TCEP pH 7.6 (buffer A) and lysed by
sonication for 5min (pulsed 5 s on, 10 s off). The lysate was clariﬁed
by centrifugation at 4 C for 40min at 30,310 RCF in a Sorvall RC6
Plus centrifuge. The supernatant was passed through a 0.2 mm sy-
ringe ﬁlter and applied to a Ni-NTA column. The bound protein was
washed with 15 C V buffer A and eluted with 10 C V buffer A con-
taining 250mM imidazole. The eluent was mixed with 20% v/v
glycerol (20mL ﬁnal volume), and stored at80 C in 1mL aliquots.Conﬂicts of interest
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